v3.26.1
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS
6 Months Ended
Jun. 30, 2026
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS  
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS

NOTE 16 – CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS

 

A condensed consolidating balance sheet of the Company as of June 30, 2026 follows:

 

 

 

Yubo International Biotech Limited (Parent Company)

 

 

Platinum (Cayman Island) and Platinum HK

(Cayman Island)

 

 

Yubo

Global

 

 

Yubo Chengdu

(WFOE)

 

 

Yubo Beijing (VIE

Subsidiaries)

 

 

Elimination

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Current Assets

 

$

 

 

$359

 

 

$75,647

 

 

$

 

 

$507,092

 

 

$

 

 

$583,098

 

Investment in subsidiaries and variable interest entity (VIE)

 

 

(2,181,987 )

 

 

930,000

 

 

 

 

 

 

 

 

 

538,607

 

 

 

713,380

 

 

 

 

Intercompany receivables

 

 

 

 

 

 

 

 

459,305

 

 

 

 

 

 

923,595

 

 

 

(1,382,900 )

 

 

 

Other assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

89,173

 

 

 

 

 

 

89,173

 

Total Assets

 

$(2,181,987 )

 

$930,359

 

 

 

534,952

 

 

 

 

 

 

2,058,467

 

 

 

(669,520 )

 

 

672,272

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

$

 

 

$150,000

 

 

$53,704

 

 

$

 

 

$3,123,894

 

 

$

 

 

$3,327,598

 

Intercompany payables

 

 

 

 

 

 

 

 

46,249

 

 

 

 

 

 

1,336,650

 

 

 

(1,382,900 )

 

 

 

Other liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Liabilities

 

 

 

 

 

150,000

 

 

 

99,954

 

 

 

 

 

 

4,460,544

 

 

 

(1,382,900 )

 

 

3,327,598

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders' Deficit:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital stock and additional paid in capital

 

 

 

 

 

1,569,229

 

 

 

878,840

 

 

 

 

 

 

4,823,148

 

 

 

(1,631,914 )

 

 

5,639,303

 

Accumulated deficit

 

 

(2,181,987 )

 

 

(788,870 )

 

 

(443,842 )

 

 

 

 

 

(7,191,211 )

 

 

2,345,294

 

 

 

(8,260,616 )

Accumulated other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,278 )

 

 

 

 

 

(1,278 )

Non—controlling interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(32,736 )

 

 

 

 

 

(32,736 )

Total Deficit

 

 

(2,181,987 )

 

 

780,359

 

 

 

434,998

 

 

 

 

 

 

(2,402,077 )

 

 

713,380

 

 

 

(2,655,327 )

Total Liabilities and Shareholders' Equity

 

$(2,181,987 )

 

$930,359

 

 

$534,952

 

 

$

 

 

$2,058,467

 

 

$(669,520 )

 

$672,272

 

 

A condensed consolidating statement of operations of the Company for the six months ended June 30, 2026:

 

 

 

Yubo International Biotech Limited (Parent Company)

 

 

Platinum (Cayman Island) and Platinum HK

(Cayman Island)

 

 

Yubo

Global

 

 

Yubo Chengdu

(WFOE)

 

 

Yubo Beijing (VIE

Subsidiaries)

 

 

Elimination

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales of product and services

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

Cost of goods and services sold

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

528,135

 

 

 

 

 

 

528,135

 

Loss from operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(528,135 )

 

 

 

 

 

(528,135 )

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(35,612 )

 

 

 

 

 

(35,612 )

Equity in net loss of subsidiaries and variable interest entity (VIE)

 

 

(2,402,077 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,402,077

 

 

 

 

Net Loss

 

$(2,402,077 )

 

$

 

 

$

 

 

$

 

 

$(563,747 )

 

$2,402,077

 

 

$(563,747 )